German Pharmaceutical Location: Risk of Over-Regulation

Germany's pharmaceutical industry association, BPI (Bundesverband der Pharmazeutischen Industrie), has voiced concerns over government plans to increase regulatory measures in the pharmaceutical sector. The Health Financing Commission (Finanzkommission Gesundheit) is preparing reform proposals for the healthcare system, which reportedly include stricter evaluations for drug innovations.

BPI's Managing Director, Dr. Kai Joachimsen, specifically criticizes the idea of "continuous evaluations of added benefit" for new drugs, even without specific triggers. Such ongoing assessments, alongside a strengthened cost-benefit analysis, would significantly increase bureaucracy and risk for pharmaceutical companies. Joachimsen points out that Germany already has approximately 35 regulatory instruments to control drug prices, and new measures could lead to a "regulatory spiral."

The association fears that the proposed changes, such as continuous benefit evaluations and enhanced cost-benefit analysis, could jeopardize patient access to new treatments, deter research and development investments, and limit therapeutic diversity. BPI emphasizes that existing mechanisms already allow for price renegotiations and re-evaluations, for instance, when sales thresholds are exceeded.

The Health Financing Commission aims to develop a more efficient healthcare system by the end of 2026. However, BPI warns that further regulation without clear benefit might weaken Germany's position as a key player in the pharmaceutical industry and harm its international competitiveness. The association calls for a clear and predictable regulatory framework to avoid an escalating cycle of regulations.